1. Updates in Lung Cancer: Insights From Vienna

2. Biomarkers in Lung Cancer

3. Tumor Mutation Burden and Response to PD-1/PD-L1 Targeted Therapies

4. Tumor Mutation Burden as a Biomarker for Atezolizumab Response

5. First-Line Atezolizumab in PD-L1-Selected Patients With NSCLC

6. Second-Line Atezolizumab in PD-L1-Selected Patients With NSCLC

7. Atezolizumab Arm of POPLAR Trial in Unselected Patients

8. EGFR TKIs in Lung Cancer

9. Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC

10. AURA3 Results

11. Icotinib in NSCLC With Brain Metastases Harboring EGFR Mutations

12. Erlotinib Plus Ramucirumab in First-Line EGFR Mutation+ Stage IV NSCLC

13. First-Line Afatinib vs Gefitinib in EGFR Mutation+ Advanced NSCLC LUX-Lung 7

14. Second-Line Afatinib for Advanced Squamous Cell Carcinoma LUX-Lung 8

15. Checkpoint Inhibitors in First-Line Therapy for NSCLC

16. Nivolumab in NSCLC Long-Term Outcomes From CheckMate 012

17. First-Line Atezolizumab in NSCLC Updated Data From BIRCH Study

18. First-Line Avelumab in Advanced NSCLC

19. Efficacy and Safety of Pembrolizumab Added to Chemotherapy

20. Efficacy and Safety of Pembrolizumab Added to Chemotherapy (cont)

21. Checkpoint Inhibitors in Mesothelioma and SCLC

22. Pembrolizumab in SCLC Cohort of KEYNOTE-028

23. Nivolumab  Ipilimumab in Recurrent SCLC

24. Pembrolizumab in Malignant Pleural Mesothelioma Cohort of KEYNOTE-028

25. Pembrolizumab in Patients With Malignant Mesothelioma Interim Analysis

26. Nivolumab in Malignant Pleural Mesothelioma

27. ALK and Other Targets in Lung Cancer

28. First-Line Ceritinib in ALK+ NSCLC (ASCEND-4)

29. Alectinib vs Crizotinib in ALK+ NSCLC Primary Results from J-ALEX

30. Brigatinib in ALK+ NSCLC With Intracranial CNS Metastases

31. Lorlatinib (PF-06463922) in Advanced ALK+ or ROS1+ NSCLC

32. Crizotinib in ROS1-Rearranged or MET- Deregulated NSCLC

33. Rovalpituzumab Tesirine in SCLC

34. Liquid Biopsy in Lung Cancer

35. Plasma ctDNA Analysis of T790M Mutation-Positive Subgroup in AURA3

36. AURA3 Plasma ctDNA Analysis Results

37. Detecting T790M Mutations by Droplet Digital PCR

38. EGFR T790M Predicts TKI Response

39. Abbreviations

40. Abbreviations (cont)

41. Abbreviations (cont)